echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Another batch of pharmaceutical companies has stopped production and cancelled!

    Another batch of pharmaceutical companies has stopped production and cancelled!

    • Last Update: 2022-01-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On January 4, 2022, the Yunnan Provincial Food and Drug Administration issued a production suspension announcement
    .
    The announcement shows that Kunming Xuanqing Biotechnology Co.
    , Ltd.
    applied for the cancellation of the "Drug Production License" and terminated the production of drugs

    .
    The cancellation of the application complies with the relevant laws and regulations, and has been studied by the Yunnan Provincial Drug Administration and agreed to be cancelled

    .
    According to public information, Kunming Xuanqing Biotechnology Co.
    , Ltd.
    was established in July 2011.
    It is a modern and new type of enterprise that develops, produces, processes and sells health and nourishing health products such as Panax notoginseng, Tianma, Maca, tea, and Chinese herbal pieces.

    .
    The company's business scope includes biotechnology research, development and consulting; sales of prepackaged food, bulk food and health food; production and sales of Chinese herbal medicine; processing, acquisition and sales of agricultural and sideline products; import and export business of goods; food production and sales; planting of Chinese medicinal materials; production, processing and sales of tea; drug technology research and development and technology promotion (projects subject to approval according to law, business activities can only be carried out after approval by relevant departments)

    .
    According to the company's news, the company changed its investors (equity) on December 23, 2021, and on the same day, the senior management personnel (directors, supervisors, managers, etc.
    ) were filed

    .
    According to statistics, since December 2021, many pharmaceutical companies have suspended production and cancelled

    .
    For example, on December 31, 2021, the Hunan Provincial Food and Drug Administration issued an announcement saying that according to the application of Huaihua Longyuan Pharmaceutical Co.
    , Ltd.
    Ethnic Traditional Chinese Medicine Piece Factory and Zhijiang Dong Autonomous County Medicinal Material Company Traditional Chinese Medicine Piece Factory, the provincial bureau canceled this according to law.
    "Drug Production License" and "Drug GMP Certificate" for two Chinese herbal decoction pieces factories

    .
    The Guangxi Zhuang Autonomous Region Food and Drug Administration also issued an announcement on December 31, 2021.
    The Guangxi Food and Drug Administration organized a special pharmacovigilance inspection of related companies.
    A total of 39 pharmaceutical companies were inspected this time, of which 33 pharmaceutical companies.
    The inspection results meet the requirements , 2 companies are not in production, and 4 pharmaceutical companies are in a state of discontinuation

    .
    It is understood that some of these drug companies that have stopped production are due to defects, and some are voluntarily applying to suspend production

    .
    According to relevant regulations, from the date of cancellation, these pharmaceutical companies will no longer be able to engage in any form of drug production activities.

    .
    On December 21, the Jiangsu Provincial Food and Drug Administration issued a notice on unannounced inspections of medical device manufacturers

    .
    According to the notification, according to the "Regulations on the Supervision and Administration of Medical Devices" and the "Quality Management Practice for Medical Device Production" and other relevant regulations, the Jiangsu Provincial Food and Drug Administration, from September 13 to October 22, 2021, failed to pass the quality random inspection.
    28 medical device manufacturers with many adverse events, complaints and reports, no self-inspection of the quality system or zero defects in the self-inspection of the quality system, and poor operation of the quality system conducted cross unannounced inspections

    .
    After inspection and risk consultation, 12 enterprises need to stop production for rectification

    .
    At the same time, the Jiangsu Provincial Food and Drug Administration stated that the above-mentioned enterprises can resume production only after the above-mentioned enterprises have completed the rectification and have been re-examined and announced by the bureau

    .
    In addition, according to media sources, in response to and cooperating with local epidemic control requirements, as of the evening of December 13, there were three listed pharmaceutical companies in Zhejiang that had announced temporary suspension of production

    .
    Among them, Zhejiang Guobang and Zhejiang Dongying, the wholly-owned subsidiaries of Guobang Pharmaceutical, temporarily suspended production in an orderly manner.
    On December 10, Yaoshi Technology also issued an announcement saying that according to relevant epidemic prevention requirements, Zhejiang Huishi Pharmaceutical, a holding subsidiary of Yaoshi Technology, will be in accordance with the requirements.
    , has begun to gradually reduce the amount and orderly temporarily suspend production on the afternoon of December 9.
    The specific time for normal production and operation will be arranged according to the government's epidemic control requirements

    .
    However, both Guobang Pharmaceutical and Yaoshi Technology said that the impact of the suspension of their subsidiaries on the company's overall performance in 2021 is relatively limited

    .
    Judging from the above announcement, in addition to the defects in the enterprise quality management system and the impact of the epidemic, most of the enterprises have recently applied for the cancellation of the "Drug Production License" and "Drug Distribution License" on their own

    .
    It can also be seen that the pharmaceutical industry is undergoing transformation and upgrading, and a benign situation of survival of the fittest is accelerating

    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.